Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Frediani

Showing results (211-220 of 336) with videos related to

Pageof 34
Sort By:
Journal of Clinical Medicine|November 25, 2023
Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian StudyMarco Sebastiani, Vincenzo Venerito, Elenia Laurino, et al.
Clinical Rheumatology|April 21, 2021
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registryMarco Sebastiani, Vincenzo Venerito, Serena Bugatti, et al.
Ocular Immunology and Inflammation|November 4, 2017
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related UveitisClaudia Fabiani, Jurgen Sota, Antonio Vitale, et al.
Clinical Rheumatology|November 18, 2016
Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational studyClaudia Fabiani, Antonio Vitale, Giacomo Emmi, et al.
Clinical Rheumatology|June 24, 2014
The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in ItalyLuca Cantarini, Antonio Vitale, Orso Maria Lucherini, et al.
Journal of Medical Virology|May 30, 2020
Serum KL-6 concentrations as a novel biomarker of severe COVID-19Miriana d'Alessandro, Paolo Cameli, Rosa Metella Refini, et al.
Clinical Rheumatology|April 4, 2018
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitisClaudia Fabiani, Antonio Vitale, Giacomo Emmi, et al.
The British Journal of Ophthalmology|August 28, 2017
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up studyClaudia Fabiani, Jurgen Sota, Antonio Vitale, et al.
Mediators of Inflammation|July 26, 2014
Biological treatments in Behçet's disease: beyond anti-TNF therapyFrancesco Caso, Luisa Costa, Donato Rigante, et al.
Clinical Rheumatology|April 20, 2018
Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumabClaudia Fabiani, Antonio Vitale, Donato Rigante, et al.
Pageof 34

Showing results (211-220 of 336) with videos related to

Sort By:
Pageof 34
Journal of Clinical Medicine|November 25, 2023
Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian StudyMarco Sebastiani, Vincenzo Venerito, Elenia Laurino, et al.
Clinical Rheumatology|April 21, 2021
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registryMarco Sebastiani, Vincenzo Venerito, Serena Bugatti, et al.
Ocular Immunology and Inflammation|November 4, 2017
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related UveitisClaudia Fabiani, Jurgen Sota, Antonio Vitale, et al.
Clinical Rheumatology|November 18, 2016
Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational studyClaudia Fabiani, Antonio Vitale, Giacomo Emmi, et al.
Clinical Rheumatology|June 24, 2014
The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in ItalyLuca Cantarini, Antonio Vitale, Orso Maria Lucherini, et al.
Journal of Medical Virology|May 30, 2020
Serum KL-6 concentrations as a novel biomarker of severe COVID-19Miriana d'Alessandro, Paolo Cameli, Rosa Metella Refini, et al.
Clinical Rheumatology|April 4, 2018
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitisClaudia Fabiani, Antonio Vitale, Giacomo Emmi, et al.
The British Journal of Ophthalmology|August 28, 2017
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up studyClaudia Fabiani, Jurgen Sota, Antonio Vitale, et al.
Mediators of Inflammation|July 26, 2014
Biological treatments in Behçet's disease: beyond anti-TNF therapyFrancesco Caso, Luisa Costa, Donato Rigante, et al.
Clinical Rheumatology|April 20, 2018
Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumabClaudia Fabiani, Antonio Vitale, Donato Rigante, et al.
Pageof 34